
Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm
Several FDA approvals have expanded the previously sparse small cell lung cancer (SCLC) treatment armamentarium, shifting the standard of care (SOC) beyond traditional chemotherapy and toward immunotherapy-based strategies in both limited-stage SCLC (LS- …